<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02486315</url>
  </required_header>
  <id_info>
    <org_study_id>NCTC005</org_study_id>
    <nct_id>NCT02486315</nct_id>
  </id_info>
  <brief_title>Treatment of Coronary ARtery bIfurcation Narrowing by AXxess Stent Implantation</brief_title>
  <acronym>CARINAX</acronym>
  <official_title>Treatment of Coronary ARtery bIfurcation Narrowing by AXxess Stent Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Mediterranea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Mediterranea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Axxess™ Biolimus A9™ Eluting Coronary Bifurcation Stent System (AXXESS System;
      Biosensors, International, Morges, Switzerland) is a dedicated bifurcation stent, designed to
      cover the lesion at the level of the carina. Although deemed ideal for lesions involving only
      the proximal MV (1,0,0 according to Medina classification ref), this device may be used also
      in more complex bifurcation lesions when additional DES are required in the distal MV and/or
      in the SB. In the present registry the investigators report the performance and the efficacy
      of the self-expanding biolimus-eluting AxxessTM stent for the treatment of bifurcation
      lesions in a real-world population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite a comprehensive understanding of the physiological and technical issues regarding the
      coronary bifurcations lesions, percutaneous coronary intervention (PCI) in this setting
      remains challenging. When compared with non-bifurcation lesions, treatment of bifurcation
      lesions is associated with increased adverse clinical events and inferior angiographic
      outcomes including procedural complications. This is due to several technical challenges,
      including both anatomical (proximal-to-distal vessel mismatch [tapering], angulation and
      calcification) and procedural (plaque shift, and side-branch [SB] closure) features. Current
      balloon-expandable drug-eluting stent (DES) have not been designed to treat the bifurcation
      lesions; in particular, the inability of DES to adequately scaffold and preserve the ostium
      of SB represents a the major reason of failure, because this is the most common site for
      restenosis. Recently a large variety of dedicated bifurcation stents have been developed in
      order to 1) provide an easier access to the SB and to scaffold more effectively its ostium,
      and 2) adapt to main vassel (MV) tapering, and to the bifurcation anatomy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>9 Months</target_duration>
  <primary_outcome>
    <measure>device success</measure>
    <time_frame>intraprocedural</time_frame>
    <description>successful deployment of the AxxessTM stent into the target lesion, without system failure or device-related complication.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">163</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>AXXESS stent</arm_group_label>
    <description>all consecutive patients with de novo bifurcation lesions treated at the Clinica Mediterranea (Naples) and at the &quot;Sapienza&quot; University (Rome) were screened for potential inclusion in the present study. Inclusion angiographic criteria were: 1) significant (≥70% diameter stenosis) bifurcation lesion; 2) MV reference diameter between 2.75 and 4.75 mm by visually estimated, 3) SB reference diameter ≥2.25 mm by visual estimate; 4) bifurcation angle (between the distal MV and the SB) &lt;70° by visual estimate. Both protected and unprotected left main bifurcation lesions were allowed to be included, provided that all previous angiographic criteria were satisfied. Patients deemed eligible underwent AXXESS stent implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AXXESS stent</intervention_name>
    <description>Axxess stent is a conically-shaped, self-expanding nitinol stent, with a 0.006-inch strut thickness, specifically designed to preserve and to match the anatomy of the bifurcation at the carina level. The stent is coated with Biolimus A9™, a highly lipophilic, semi-synthetic sirolimus analogue, immersed in the biodegradable polylactic acid (PLA) applied primarily to the abluminal surface. PLA completely dissolves after 6 to 9 months.The stent has 3 radiopaque markers at the distal end and one at the proximal end to aid in the visibility and placement. The AxxessTM stent is 7 Fr guiding catheter or Sheathless Guiding Catheter compatible. During the study period, the AxxessTM stent was available in 3 different diameters (3.0, 3.5 and 4.0 mm) and lengths (9, 10 and 14 mm)</description>
    <arm_group_label>AXXESS stent</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all consecutive patients with de novo bifurcation lesions treated at the Clinica
        Mediterranea (Naples) and at the &quot;Umberto I&quot; University (Rome) were screened for potential
        inclusion in the present study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. significant (≥70% diameter stenosis) bifurcation lesion;

          2. MV reference diameter between 2.75 and 4.75 mm by visually estimated

          3. SB reference diameter ≥2.25 mm by visual estimate;

          4. bifurcation angle (between the distal MV and the SB) &lt;70° by visual estimate

        Exclusion Criteria:

          1. patients with contraindications to prolonged dual-antiplatelet therapy,

          2. known sensitivity to &quot;limus&quot; compounds, stainless steel, titanium, or nickel;

          3. inclusion in others studies on bifurcation lesions; and

          4. all bifurcation lesions not satisfying the angiographic inclusion criteria reported
             above
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Briguori, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Mediterranea</affiliation>
  </overall_official>
  <reference>
    <citation>Latib A, Colombo A. Bifurcation disease: what do we know, what should we do? JACC Cardiovasc Interv. 2008 Jun;1(3):218-26. doi: 10.1016/j.jcin.2007.12.008. Review.</citation>
    <PMID>19463303</PMID>
  </reference>
  <reference>
    <citation>Wykrzykowska JJ, Grundeken MJ, Stankovic G, Di Mario C. Is there a need for dedicated devices? EuroIntervention. 2015;11 Suppl V:V139-42. doi: 10.4244/EIJV11SVA31.</citation>
    <PMID>25983149</PMID>
  </reference>
  <reference>
    <citation>Grube E, Buellesfeld L, Neumann FJ, Verheye S, Abizaid A, McClean D, Mueller R, Lansky A, Mehran R, Costa R, Gerckens U, Trauthen B, Fitzgerald PJ. Six-month clinical and angiographic results of a dedicated drug-eluting stent for the treatment of coronary bifurcation narrowings. Am J Cardiol. 2007 Jun 15;99(12):1691-7. Epub 2007 May 7.</citation>
    <PMID>17560877</PMID>
  </reference>
  <reference>
    <citation>Buysschaert I, Dubois CL, Dens J, Ormiston J, Worthley S, McClean D, Ottervanger JP, Meredith I, Uren N, Wijns W, Whitbourn R, Mehran R, Lansky AJ, Bichalska M, Meis S, Verheye S. Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study. EuroIntervention. 2013 Sep;9(5):573-81. doi: 10.4244/EIJV9I5A93.</citation>
    <PMID>24058075</PMID>
  </reference>
  <reference>
    <citation>Hasegawa T, Ako J, Koo BK, Miyazawa A, Sakurai R, Chang H, Dens J, Verheye S, Grube E, Honda Y, Fitzgerald PJ. Analysis of left main coronary artery bifurcation lesions treated with biolimus-eluting DEVAX AXXESS plus nitinol self-expanding stent: intravascular ultrasound results of the AXXENT trial. Catheter Cardiovasc Interv. 2009 Jan 1;73(1):34-41. doi: 10.1002/ccd.21765.</citation>
    <PMID>19089934</PMID>
  </reference>
  <reference>
    <citation>García E, Unzué Vallejo L, Rodríguez-Rodrigo FJ. Placement of a single Axxess stent as new treatment strategy for Medina 1,0,0 left main stem bifurcation lesion. J Invasive Cardiol. 2014 Apr;26(4):E45-7.</citation>
    <PMID>24717281</PMID>
  </reference>
  <reference>
    <citation>Louvard Y, Thomas M, Dzavik V, Hildick-Smith D, Galassi AR, Pan M, Burzotta F, Zelizko M, Dudek D, Ludman P, Sheiban I, Lassen JF, Darremont O, Kastrati A, Ludwig J, Iakovou I, Brunel P, Lansky A, Meerkin D, Legrand V, Medina A, Lefèvre T. Classification of coronary artery bifurcation lesions and treatments: time for a consensus! Catheter Cardiovasc Interv. 2008 Feb 1;71(2):175-83.</citation>
    <PMID>17985377</PMID>
  </reference>
  <reference>
    <citation>Lassen JF, Holm NR, Stankovic G, Lefèvre T, Chieffo A, Hildick-Smith D, Pan M, Darremont O, Albiero R, Ferenc M, Louvard Y. Percutaneous coronary intervention for coronary bifurcation disease: consensus from the first 10 years of the European Bifurcation Club meetings. EuroIntervention. 2014 Sep;10(5):545-60. doi: 10.4244/EIJV10I5A97.</citation>
    <PMID>25256198</PMID>
  </reference>
  <reference>
    <citation>Medina A, Suárez de Lezo J, Pan M. [A new classification of coronary bifurcation lesions]. Rev Esp Cardiol. 2006 Feb;59(2):183. Spanish.</citation>
    <PMID>16540043</PMID>
  </reference>
  <reference>
    <citation>Noguchi T, Miyazaki MD S, Morii I, Daikoku S, Goto Y, Nonogi H. Percutaneous transluminal coronary angioplasty of chronic total occlusions. Determinants of primary success and long-term clinical outcome. Catheter Cardiovasc Interv. 2000 Mar;49(3):258-64.</citation>
    <PMID>10700054</PMID>
  </reference>
  <reference>
    <citation>Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S. Third universal definition of myocardial infarction. Circulation. 2012 Oct 16;126(16):2020-35. doi: 10.1161/CIR.0b013e31826e1058. Epub 2012 Aug 24.</citation>
    <PMID>22923432</PMID>
  </reference>
  <reference>
    <citation>Behan MW, Holm NR, Curzen NP, Erglis A, Stables RH, de Belder AJ, Niemelä M, Cooter N, Chew DP, Steigen TK, Oldroyd KG, Jensen JS, Lassen JF, Thuesen L, Hildick-Smith D. Simple or complex stenting for bifurcation coronary lesions: a patient-level pooled-analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. Circ Cardiovasc Interv. 2011 Feb 1;4(1):57-64. doi: 10.1161/CIRCINTERVENTIONS.110.958512. Epub 2011 Jan 4.</citation>
    <PMID>21205942</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>June 30, 2015</last_update_submitted>
  <last_update_submitted_qc>June 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinica Mediterranea</investigator_affiliation>
    <investigator_full_name>Carlo Briguori</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>coronary bifurcation</keyword>
  <keyword>coronary stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

